Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Repurposing Ibrutinib for Chemo-Immunotherapy in a Phase 1b Study of Ibrutinib With Indoximod Plus Metronomic Cyclophosphamide and Etoposide for Pediatric Patients With Brain Cancer

Next Previous
X
Search
Trial Profile

Repurposing Ibrutinib for Chemo-Immunotherapy in a Phase 1b Study of Ibrutinib With Indoximod Plus Metronomic Cyclophosphamide and Etoposide for Pediatric Patients With Brain Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Etoposide (Primary) ; Ibrutinib (Primary) ; Indoximod (Primary)
  • Indications Brain cancer; Ependymoma; Glioblastoma; Medulloblastoma; Primitive neuroectodermal tumours
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2024 Results of pooled analysis studying effect of indoximod-based chemo-immunotherapy((n=27, NCT02502708, NCT04049669) or (n=3, NCT05106296)) , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 19 Apr 2023 Results assessing whether immunotherapy designed to enhance immunogenic antigen-presentation during chemotherapy produces extensive reactivation of precursor T cells by selecting Informative patients from NCT04049669 and NCT05106296, presented at the 114th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top